At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 81 enrolled
Drug / intervention
Levetiracetamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial
In Brief
A Phase 4 clinical trial evaluating Levetiracetam for Brain Neoplasms and 5 related conditions. Completed, enrolled 81 participants across 1 site.
Detailed Summary
The purpose of this study is to see if there are any differences in patient reported neurotoxicity between patients who receive Levetiracetam tablets for one week after surgery to remove a brain tumor versus those who receive Levetiracetam tablets for six weeks after surgery. Specifically, we will see if one group has less side effects than the other, and whether or not one group has more seizures than the other.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Neoplasms, Brain Cancer, Brain Tumors, Cancer of the Brain, Cancer of Brain, Seizure
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartAug 2015
Primary CompletionOct 2020
TodayJul 2026
First PostedJan 8, 2015
Enrollment StartAug 5, 2015
Primary CompletionOct 7, 2020
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 11.5 years ago
Interventions
Levetiracetamdrug